Literature DB >> 26936392

Engineered Theranostic Magnetic Nanostructures: Role of Composition and Surface Coating on Magnetic Resonance Imaging Contrast and Thermal Activation.

Vikas Nandwana1, Soo-Ryoon Ryoo1, Shanthi Kanthala1, Mrinmoy De2, Stanley S Chou3, Pottumarthi V Prasad4, Vinayak P Dravid1.   

Abstract

Magnetic nanostructures (MNS) have emerged as promising functional probes for simultaneous diagnostics and therapeutics (theranostic) applications due to their ability to enhance localized contrast in magnetic resonance imaging (MRI) and heat under external radio frequency (RF) field, respectively. We show that the "theranostic" potential of the MNS can be significantly enhanced by tuning their core composition and architecture of surface coating. Metal ferrite (e.g., MFe2O4) nanoparticles of ∼8 nm size and nitrodopamine conjugated polyethylene glycol (NDOPA-PEG) were used as the core and surface coating of the MNS, respectively. The composition was controlled by tuning the stoichiometry of MFe2O4 nanoparticles (M = Fe, Mn, Zn, ZnxMn1-x) while the architecture of surface coating was tuned by changing the molecular weight of PEG, such that larger weight is expected to result in longer length extended away from the MNS surface. Our results suggest that both core as well as surface coating are important factors to take into consideration during the design of MNS as theranostic agents which is illustrated by relaxivity and thermal activation plots of MNS with different core composition and surface coating thickness. After optimization of these parameters, the r2 relaxivity and specific absorption rate (SAR) up to 552 mM(-1) s(-1) and 385 W/g were obtained, respectively, which are among the highest values reported for MNS with core magnetic nanoparticles of size below 10 nm. In addition, NDOPA-PEG coated MFe2O4 nanostructures showed enhanced biocompatibility (up to [Fe] = 200 μg/mL) and reduced nonspecific uptake in macrophage cells in comparison to other well established FDA approved Fe based MR contrast agents.

Entities:  

Keywords:  biomedical applications; hyperthermia; magnetic nanoparticles; magnetic nanostructures; magnetic resonance imaging contrast; nanomedicine; theranostics; thermal activation

Mesh:

Substances:

Year:  2016        PMID: 26936392     DOI: 10.1021/acsami.6b01377

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  6 in total

Review 1.  Magnetic resonance imaging-guided and targeted theranostics of colorectal cancer.

Authors:  Yanan Li; Jingqi Xin; Yongbing Sun; Tao Han; Hui Zhang; Feifei An
Journal:  Cancer Biol Med       Date:  2020-05-15       Impact factor: 4.248

2.  MRI Detectable Polymer Microspheres Embedded With Magnetic Ferrite Nanoclusters For Embolization: In Vitro And In Vivo Evaluation.

Authors:  Xiao-Ya Qin; Xiao-Xin Liu; Zi-Yuan Li; Li-Ying Guo; Zhuo-Zhao Zheng; Hai-Tao Guan; Li Song; Ying-Hua Zou; Tian-Yuan Fan
Journal:  Int J Nanomedicine       Date:  2019-11-18

3.  Aβ oligomer induced cognitive impairment and evaluation of ACU193-MNS-based MRI in rabbit.

Authors:  Nicholas B Rozema; Daniele Procissi; Nicola Bertolino; Kirsten L Viola; Vikas Nandwana; Nafay Abdul; Sophia Pribus; Vinayak Dravid; William L Klein; John F Disterhoft; Craig Weiss
Journal:  Alzheimers Dement (N Y)       Date:  2020-10-10

4.  Effect of different molecular coatings on the heating properties of maghemite nanoparticles.

Authors:  Marco Sanna Angotzi; Valentina Mameli; Shankar Khanal; Miroslav Veverka; Jana Vejpravova; Carla Cannas
Journal:  Nanoscale Adv       Date:  2021-11-08

5.  Nanoparticle architecture preserves magnetic properties during coating to enable robust multi-modal functionality.

Authors:  Lauren E Woodard; Cindi L Dennis; Julie A Borchers; Anilchandra Attaluri; Esteban Velarde; Charlene Dawidczyk; Peter C Searson; Martin G Pomper; Robert Ivkov
Journal:  Sci Rep       Date:  2018-08-23       Impact factor: 4.379

6.  The Therapeutic and Diagnostic Potential of Amyloid β Oligomers Selective Antibodies to Treat Alzheimer's Disease.

Authors:  Kirsten L Viola; Maira A Bicca; Adrian M Bebenek; Daniel L Kranz; Vikas Nandwana; Emily A Waters; Chad R Haney; Maxwell Lee; Abhay Gupta; Zachary Brahmbhatt; Weijian Huang; Ting-Tung Chang; Anderson Peck; Clarissa Valdez; Vinayak P Dravid; William L Klein
Journal:  Front Neurosci       Date:  2022-01-03       Impact factor: 5.152

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.